clinical trial Archives
Dec. 5, 2019—The Vanderbilt Maternal Addiction Recovery Program is participating in a 12-site clinical trial that will compare two forms of the medication buprenorphine in treating opioid use disorder during pregnancy, and the results could have a potentially significant impact on clinical practice.
Jul. 8, 2019—A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.
Feb. 21, 2019—A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.
Jan. 28, 2019—Vanderbilt vaccine researchers are enrolling adult volunteers in a National Institutes of Health (NIH)-sponsored Phase II clinical trial that will study a next generation pertussis vaccine that may protect people from whooping cough.
Mar. 22, 2018—The rates of myopia, or nearsightedness, in pediatric patients have steadily increased with little to no change in treatment, which, for decades, has had ophthalmologists and optometrists turning to corrective lenses for improved vision.
Jan. 4, 2018—The growing list of patients needing liver transplants continues to outpace the number of available donor organs, but a new preservation and transport device for donor livers could possibly make a big difference.
Oct. 26, 2017—Vanderbilt researcher Tonia Rex, Ph.D., is accustomed to performing studies in her lab with a goal of translating the findings into better diagnoses and treatment tools for the visually impaired.
Oct. 26, 2017—Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.
Aug. 31, 2017—Vanderbilt University Medical Center (VUMC) is studying the safety of a possible treatment for diabetic kidney disease that would delay or prevent the need for kidney replacement such as dialysis.
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.